Business Directory, Press Releases, Jobs, Products, Services, Articles
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | News on Your Site

Press Releases

iHealthcareAnalyst, Inc.

Press Release

Receive press releases from iHealthcareAnalyst, Inc.: By Email RSS Feeds:

Global Epigenetics Drugs Market Analysis: Drug Type, Mechanism of Action, Growth Trends and Forecast to 2020, New Findings by iHealthcareAnalyst, Inc.

Epigenetics Drugs Market by Drug Type (ChiP Technology, DNA Methylation), and Mechanism of Action – DNMT Inhibitors – Azacitidine (Vidaza) and Decitabine (Dacogen); and HDAC Inhibitors or HDIs – Romidepsin (Istodax), Vorinostat (Zolinza) 2016-2020

Maryland Heights, MO, February 18, 2017 --( The global epigenetics drugs market is estimated to reach USD 5.8 Billion in 2020, declining at a CAGR of 18.3% from 2016 to 2020, due to increasing demand for cancer, heart diseases, diabetes, and mental illnesses treatment worldwide. The global epigenetics drugs market growth mainly is driven by factors such as rising incidence of cancer, advancements in screening tools and huge sum invested in research and development activities. The impact of DNMT inhibitors is highly significant for inhibiting the cell cycle growth, and these inhibitors by their mechanism of action account for the major share of the global epigenetics drugs market.

Browse Epigenetics Drugs Market by Drug Type (ChiP Technology, DNA Methylation), and Mechanism of Action – DNMT Inhibitors – Azacitidine (Vidaza) and Decitabine (Dacogen); and HDAC Inhibitors or HDIs – Romidepsin (Istodax), Vorinostat (Zolinza) 2016-2020 at

Epigenetics is a study of change in the gene expression without any change in gene sequence. Epigenetic changes beyond a normal expression pattern can cause a variety of diseases. Epigenetic therapy involves use of drugs or other epigenome-influencing techniques to treat medical conditions including cancer, heart disease, diabetes, and mental illnesses. Epigenetics regulates gene expression in a reversible manner by chemically modifying DNA and histone proteins, which prevent permanent mutations or alterations within the genes or genome itself.

The global epigenetics drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (ChIP technology, DNA methylation), and their mechanism of action such as DNMT inhibitors - Azacitidine (vidaza) and Decitabine (dacogen); and HDAC inhibitors or HDIs - Romidepsin (istodax), Vorinostat (zolinza), and forecasts growth trends (CAGR% - 2016 to 2020). The global epigenetics drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global epigenetics drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major players operating in the global epigenetics drugs market and included in this report are Celgene Corporation, Eisai Pharmaceuticals, Pharmacyclics Inc., Merck & Co Inc. and others.

To request Table of Contents and Sample Pages of this report visit:

About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Contact Information
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508

Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.
Promote Your Business